Back to top
more

OncoMed Pharmaceuticals, Inc. (OMED)

(Delayed Data from NSDQ)

$0.89 USD

0.89
NA

0.00 (0.00%)

Updated Apr 22, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[OMED]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Industry: Medical - Biomedical and Genetics

Record: 1

12/07/2018

Company Report

Pages: 6

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

12/06/2018

Company Report

Pages: 7

OncoMed and Mereo BioPharma Announce Proposed Merger; PT to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

11/06/2018

Company Report

Pages: 8

3Q18 Results; Platform Progress Heading Into SITC Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OMED

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

10/22/2018

Company Report

Pages: 8

OncoMed Reports Overall Clinical Benefit Rate of 85% in Interim Phase 1b Data in Ovarian Cancer at ESMO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

10/18/2018

Daily Note

Pages: 3

OncoMed Indicates Celgene Not Exercising Rosmantuzumab License Option

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

09/24/2018

Daily Note

Pages: 3

OncoMed Announces Publication of Single-Agent Navicixizumab Phase 1a Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

09/20/2018

Company Report

Pages: 8

OncoMed Announces Celgene Not Exercising Option to License Navicixizumab; PT Lowered to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

09/07/2018

Company Report

Pages: 8

Global Investment Conference: OncoMed Takeaways; Navicixizumab and Pipeline Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

08/02/2018

Company Report

Pages: 8

2Q18 Results; Focus Remains on Navicixizumab in Ovarian Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

05/14/2018

Company Report

Pages: 7

1Q18 Results: Pipeline Progressing According to Plan

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

03/20/2018

Daily Note

Pages: 3

Announces John Lewicki, PhD, as CEO; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

03/09/2018

Company Report

Pages: 5

4Q17 Results: Active Search for CEO Continues; Reiterate Neutral Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

02/23/2018

Company Report

Pages: 8

Waiting for Some Clarity Amidst the Chaos; Assuming Coverage With a Neutral and $3 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

05/15/2017

Company Report

Pages: 6

Removing Demcizumab and Tarextumab From Estimates; Focus Shifts to IO and Earlier CELG Collab Programs; PT to $6 From $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

04/11/2017

Company Report

Pages: 7

Demcizumab Misses in Pancreatic Cancer AND Bayer Leaves Wnt Programs; Lowering PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

03/09/2017

Company Report

Pages: 5

4Q16: Fast Approaching Key Data and Opt-In Decisions

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

11/02/2016

Company Report

Pages: 6

3Q16: Despite Development Shuffles, Focus Remains on 2017 Opt-in Decisions

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

09/22/2016

Company Report

Pages: 17

Initiating Coverage With a Buy Ahead of a Year of Possible Partner Opt-Ins

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 50.00

Research Provided by a Third Party